Tiger Brokers

Movement Alert｜Genmab A/S Intraday Rise 11.11%, Rina-S Ovarian Cancer Trial Shows 45.9% Response Rate

Market Focus
Oct 06

On October 6, Genmab A/S rose 11.11% in regular trading, trading at $38.565 per share.

The movement follows positive clinical trial results for Rina-S in platinum-resistant ovarian cancer patients. Genmab reported a 45.9% confirmed objective response rate in its Phase 1/2 study, with five patients showing no detectable signs of cancer post-treatment. The company noted median progression-free survival of 9.5 months and median duration of response of 12.1 months, with 51% of responders maintaining response at one year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10